Posted on July 28 2016
Council for Scientific and Industrial Research (CSIR) on 25 June launched in Tiruchirappalli. BGR-34 - an anti-diabetic ayurvedic drug designed for type 2 Diabetes mellitus.
“The modern diabetes drugs are known for side-effects and toxicity while BGR-34 works by controlling blood sugar and limiting the harmful effects of other drugs,” said NBRIs’ Senior Principal Scientist A.K.S. Rawat.
BGR-34 is developed jointly by National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), the research units of CSIR at Lucknow. Aimed at managing type 2 diabetes, BGR-34 has been jointly developed by National Botanical Research Institute (NBRI) and Central Institute for Medicinal and Aromatic Plants (CIMAP), both located in Lucknow.
"BGR-34 is a unique product that manages the lives of human suffering diabetics. The product passed several battery of tests and showed hypoglycaemic activity in experimental subjects," said AIMIL Pharmaceuticals vice president Anil Kumar Sharma.